세계의 인유두종 바이러스(HPV) 백신 시장 : 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 질병별, 유통 채널별, 지역별, 부문별 경쟁(2020-2030년)
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Disease, By Distribution Channel, By Region, & Competition, 2020-2030F
상품코드:1738319
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 인유두종 바이러스(HPV) 백신 시장은 2024년 83억 5,000만 달러로 평가되었고, 2030년에는 137억 7,000만 달러에 이를 전망이며, CAGR 8.65%로 성장할 것으로 예측됩니다.
이 시장은 세계의 예방접종 및 암 예방 이니셔티브의 핵심이며 HPV 관련 질환에 대한 의식의 고조 및 예방접종 캠페인의 확대에 의해 강력한 성장을 이루고 있습니다. HPV 관련 질병의 유병률 증가는 헬스케어 투자 개선 및 백신 접종 전략의 세계 구현과 함께 시장 수요를 계속 견인하고 있습니다. WHO와 GAVI와 같은 국제 보건기구의 지원은 백신에 대한 접근과 섭취를 더욱 가속화하고 있습니다. 단회 접종 백신 요법, 성별에 얽매이지 않는 백신 접종 프로그램, 추적 및 관리를 위한 디지털 헬스 기술 등의 혁신적인 접근법의 도입에 의해 세계 백신 접종율이 향상되어, HPV에 의한 암의 부담이 장기적으로 경감될 것으로 기대됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
83억 5,000만 달러
시장 규모(2030년)
137억 7,000만 달러
CAGR(2025-2030년)
8.65%
급성장 부문
자궁 경부암
최대 시장
북미
시장 성장 촉진요인
HPV 관련 질환 유병률 상승
주요 시장 과제
높은 백신 비용 및 가격 설정 제약
주요 시장 동향
성별을 포함한 예방접종 프로그램 확대
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
금액별
시장 점유율 및 예측
유형별(2가, 4가, 9가)
질병별(자궁경부암, 질암 및 외음암, 항문암, 구강인두(두경부)암, 성기사마귀)
유통 채널별(병원, 약국, 정부계 공급자, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 인유두종 바이러스 백신 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향 및 발전
최근 동향
제품 출시
합병 및 인수
제13장 세계의 인유두종 바이러스 백신 시장 : SWOT 분석
제14장 경쟁 구도
Merck & Co., Inc.
GSK plc.
Serum Institute of India Pvt. Ltd
Sanofi
Pfizer Inc.
Inovio Pharmaceuticals, Inc
Walvax Biotechnology Co., Ltd
Bharat Biotech Ltd
Johnson & Johnson Services, Inc.
Moderna, Inc.
제15장 전략적 제안
제16장 기업 소개 및 면책사항
AJY
영문 목차
영문목차
The Global Human Papillomavirus (HPV) Vaccine Market was valued at USD 8.35 Billion in 2024 and is projected to reach USD 13.77 Billion by 2030, growing at a CAGR of 8.65%. This market is a cornerstone of global immunization and cancer prevention initiatives, witnessing strong growth propelled by rising awareness of HPV-associated diseases and expanded immunization campaigns. Increased prevalence of HPV-related conditions, coupled with improved healthcare investments and the global implementation of vaccination strategies, continues to drive market demand. Support from international health bodies like WHO and GAVI has further accelerated vaccine accessibility and uptake. The introduction of innovative approaches, such as single-dose vaccine regimens, gender-neutral vaccination programs, and digital health technologies for tracking and administration, is expected to improve global vaccine coverage and reduce the burden of HPV-induced cancers over time.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 8.35 Billion
Market Size 2030
USD 13.77 Billion
CAGR 2025-2030
8.65%
Fastest Growing Segment
Cervical Cancer
Largest Market
North America
Key Market Drivers
Rising Prevalence of HPV-Related Diseases
The growing prevalence of HPV-related diseases is a major force driving the expansion of the HPV vaccine market. HPV remains one of the most common sexually transmitted infections worldwide, with current statistics indicating that approximately 10% of women globally are carriers at any given time. This widespread presence results in significant health consequences, including about 620,000 new cancer cases in women and 70,000 in men annually, largely driven by cervical, oropharyngeal, and anal cancers. With cervical cancer alone accounting for nearly 530,000 new diagnoses each year, the burden on public health systems is substantial. The increasing rate of infection has led to greater reliance on vaccination as a preventive measure, particularly in regions with high incidence rates, reinforcing the demand for HPV vaccines across both developed and developing countries.
Key Market Challenges
High Vaccine Cost and Pricing Constraints
The high cost associated with HPV vaccines presents a substantial challenge, particularly in low- and middle-income countries where the disease burden is often highest. Budget limitations within public health systems can restrict large-scale procurement, limiting vaccine access to the broader population. These pricing challenges hinder market penetration and slow down immunization program adoption in resource-constrained areas. Manufacturers and global health agencies are increasingly exploring tiered pricing models and strategic collaborations to improve affordability and expand market reach, yet cost remains a limiting factor for universal vaccine access.
Key Market Trends
Expansion of Gender-Inclusive Vaccination Programs
A notable trend in the HPV vaccine market is the shift toward gender-inclusive vaccination policies. Historically targeted at adolescent girls to prevent cervical cancer, immunization programs are now expanding to include boys and young men in response to growing evidence linking HPV to a broader spectrum of cancers, such as oropharyngeal and anal cancers. This inclusive approach significantly increases the eligible vaccination population and provides a new avenue for manufacturers and healthcare providers to improve coverage rates. Broader demographic targeting enhances the potential for widespread immunity and further supports efforts to reduce the overall incidence of HPV-related diseases globally.
Key Market Players
Merck & Co., Inc.
GSK plc.
Serum Institute of India Pvt. Ltd
Sanofi
Pfizer Inc.
Inovio Pharmaceuticals, Inc
Walvax Biotechnology Co., Ltd
Bharat Biotech Ltd
Johnson & Johnson Services, Inc.
Moderna, Inc.
Report Scope
In this report, the Global Human Papillomavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Human Papillomavirus Vaccine Market, By Type:
Bivalent
Quadrivalent
Nonavalent
Human Papillomavirus Vaccine Market, By Disease:
Cervical Cancer
Vaginal and Vulvar Cancers
Anal Cancer
Oropharyngeal (Head and Neck) Cancers
Genital Warts
Human Papillomavirus Vaccine Market, By Distribution Channel:
Hospitals and Retail Pharmacies
Government Suppliers
Others
Human Papillomavirus Vaccine Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Papillomavirus Vaccine Market.
Available Customizations
Global Human Papillomavirus Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Human Papillomavirus Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Bivalent, Quadrivalent, Nonavalent)
5.2.2. By Disease (Cervical Cancer, Vaginal and Vulvar Cancers, Anal Cancer, Oropharyngeal (Head and Neck) Cancers, Genital Warts)
5.2.3. By Distribution Channel (Hospitals and Retail Pharmacies, Government Suppliers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Human Papillomavirus Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Disease
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Human Papillomavirus Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Disease
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Human Papillomavirus Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Disease
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Human Papillomavirus Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Disease
6.3.3.2.3. By Distribution Channel
7. Europe Human Papillomavirus Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Disease
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human Papillomavirus Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Disease
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom Human Papillomavirus Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Disease
7.3.2.2.3. By Distribution Channel
7.3.3. Italy Human Papillomavirus Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Disease
7.3.3.2.3. By Distribution Channel
7.3.4. France Human Papillomavirus Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Disease
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Human Papillomavirus Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Disease
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Human Papillomavirus Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Disease
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human Papillomavirus Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Disease
8.3.1.2.3. By Distribution Channel
8.3.2. India Human Papillomavirus Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Disease
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Human Papillomavirus Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Disease
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Disease
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Human Papillomavirus Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Disease
8.3.5.2.3. By Distribution Channel
9. South America Human Papillomavirus Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Disease
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Disease
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Disease
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Disease
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Human Papillomavirus Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Disease
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Disease
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Disease
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Human Papillomavirus Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Disease
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Human Papillomavirus Vaccine Market: SWOT Analysis
